End-Stage Kidney Disease Clinical Trial
Official title:
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.
RESOLVE is a pragmatic, cluster-randomised, open-label study designed to evaluate in real-world conditions the comparative effectiveness of two default dialysate sodium concentrations. Dialysis sites will be randomised in a 1:1 ratio to a default dialysate sodium concentration of 137mmol/l or 140mmol/l. 'Default' is defined as the use of the allocated dialysate sodium for ≥ 90% of delivered dialysis sessions in the unit. All other care will be according to standard local practices as determined by the site. Outcomes will be assessed on individual patients dialysing at those sites. Sites will be asked to consent to participation while waiver or opt-out consent will be sought for individual patients. It is anticipated that site accrual will occur over 5-7 years with average study duration expected to be approximately 2-5 years. The actual length of the study will be end-point determined. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
| Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
| Completed |
NCT03582592 -
Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis
|
N/A | |
| Completed |
NCT02694068 -
Biological Determinants of Peritoneal Dialysis
|
||
| Not yet recruiting |
NCT02832505 -
Applications of MRI in Kidney Disease
|
||
| Not yet recruiting |
NCT02590081 -
Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients
|
Phase 4 | |
| Completed |
NCT01859884 -
Optimizing Kidney Transplant Informed Consent
|
N/A | |
| Completed |
NCT00509236 -
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
|
Phase 3 | |
| Completed |
NCT02009514 -
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06377293 -
Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients
|
N/A | |
| Completed |
NCT01528800 -
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
|
Phase 2 | |
| Completed |
NCT01863914 -
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
|
Phase 2 | |
| Withdrawn |
NCT06030050 -
Animal Assisted Intervention for Hemodialysis Outpatients
|
N/A | |
| Completed |
NCT04610593 -
Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis
|
N/A | |
| Recruiting |
NCT05931276 -
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
|
Phase 3 | |
| Completed |
NCT00143741 -
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
|
Phase 1 | |
| Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
| Recruiting |
NCT03142529 -
Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02342119 -
Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation
|
N/A | |
| Recruiting |
NCT05614115 -
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
|
Phase 1 |